Analysis of hormad1, fthl17 and adam29 cancer/testis specific genes expression in glioblastoma

Glioblastoma multiform (GBM, World Health Organization grade IV) is the most common and aggressive primary brain tumor. GBM is the highest grade of gliomas given the characteristic abilities of high invasion, migration, and proliferation. The median survival for GBM patients is about 14–16 months and the average 2 year and the survival rate is only 26%–33% even though they have receivedstandard care including surgical resection followed by concurrent radiotherapy and chemotherapy with temozolomide. Immunotherapy is a promising therapeutic adjuvant in fighting against this cancer.Cancer/testis antigens (CTAs) are a group of tumor-associated antigens that are typically restricted to adult testis, but they are aberrantly expressed in several types of cancers, especially in advanced cancers with stem-like characteristics. These tumor-associated antigens are immunogenic in different cancers. Finding of frequently expressed CTAs in GBM can provide effective immunotherapeutic targets to use in translational researchers on this cancer. The aim of this study was conducting an extensive expression analysis of ADAM29, HORMAD1, FTHL17 in GBM to determine whether these antigenscan be an appropriate target in immunotherapy of GBM.fifty pathologically confirmed GBM paraffin embedded tissue sample was conducted in this experiment. Total RNA was extracted from thesesamples and TaqMan based RealTime PCR technology was used to the evaluation of HORMAD, ADAM29 and FTHL17 gene expression.according to our results HORMAD1 is the most frequently expressed gene in these tissue samples. Forty-four percent of samples (22 out of 50 samples) expressed HORMAD1 in various levels. Either FTHL17 and ADAM29 were expressed in only one of samples.HORMAD1 can be a promising target in immunotherapy research targeting GBM

کلیدواژه ها:

Cancer Diagnosis ، Cancer Prevention ، Gene and Cancer ، Cell and Cancer ، Cancer Treatment and Management